{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:08:03Z","timestamp":1793156883223,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Late antibody-mediated rejection (AMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells and natural killer (NK) cells, both expressing high levels of CD38.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Here, we report the use of CD38 monoclonal antibody daratumumab (9-mo course) in a kidney allograft recipient diagnosed with smoldering myeloma and anti-HLA class II donor-specific antibody-positive chronic active AMR 13 years after transplantation. Patient monitoring included serial HLA single-antigen testing, peripheral blood immune cell phenotyping, as well as follow-up allograft and bone marrow biopsies at 3 and 9 months, including analyses of rejection-related gene expression patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Daratumumab led to persistent CD138\n                      <jats:sup>+<\/jats:sup>\n                      cell depletion in the bone marrow and blood and substantially decreased NK cells counts in blood and graft tissue. At the same time, donor-specific antibody in serum disappeared, and in vitro alloantibody production by CD138\n                      <jats:sup>+<\/jats:sup>\n                      cells enriched from bone marrow aspirates was abrogated. A 3-month follow-up biopsy revealed a complete resolution of microcirculation inflammation (g+ptc: 3 to 0) and molecular AMR activity (AMR score: 0.79 to &lt;0.2). The same biopsy showed (subclinical) tubulointerstitial inflammation, which prompted steroid treatment. Over an observation period of 12 months, graft function stabilized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Targeting CD38 for plasma cell and NK cell depletion may be an effective strategy to counteract AMR. Our results may encourage the design of future trials to clarify the role of this innovative treatment concept in organ transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000003247","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T13:41:54Z","timestamp":1585748514000},"page":"451-457","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":114,"title":["CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection"],"prefix":"10.1097","volume":"105","author":[{"given":"Konstantin","family":"Doberer","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kl\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido A.","family":"Gualdoni","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."},{"name":"Institute of Immunology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farsad","family":"Eskandary","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Farkash","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, University of Michigan Health System, Ann Arbor, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiter","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Reindl-Schwaighofer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wahrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmuth","family":"Haslacher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip F.","family":"Halloran","sequence":"additional","affiliation":[{"name":"Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/tri.13436","article-title":"The therapeutic challenge of late antibody-mediated kidney allograft rejection.","volume":"32","author":"B\u00f6hmig","year":"2019","journal-title":"Transpl Int"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection.","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial.","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial.","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/TP.0000000000002462","article-title":"Novel therapeutic approaches to allosensitization and antibody-mediated rejection.","volume":"103","author":"Jordan","year":"2019","journal-title":"Transplantation"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2015.02.004","article-title":"The perfect storm: HLA antibodies, complement, Fc\u03b3Rs, and endothelium in transplant rejection.","volume":"21","author":"Thomas","year":"2015","journal-title":"Trends Mol Med"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/TP.0000000000001586","article-title":"Evidence for CD16a-mediated NK cell stimulation in antibody-mediated kidney transplant rejection.","volume":"101","author":"Parkes","year":"2017","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology.","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future.","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma.","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use.","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"e94197","DOI":"10.1172\/jci.insight.94197","article-title":"Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.","volume":"2","author":"Reeve","year":"2017","journal-title":"JCI Insight"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/ajt.14329","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study.","volume":"17","author":"Halloran","year":"2017","journal-title":"Am J Transplant"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury.","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1089\/ars.2014.5892","article-title":"Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.","volume":"21","author":"Ejaz","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ajt.15752","article-title":"Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies.","volume":"20","author":"Madill-Thomsen","year":"2020","journal-title":"Am J Transplant"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma.","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:07:02Z","timestamp":1749049622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003247","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,26]]}}}